Literature DB >> 16044107

Inter- and intraindividual variabilities in pharmacokinetics of fentanyl after repeated 72-hour transdermal applications in cancer pain patients.

Isabelle Solassol1, Françoise Bressolle, Laetitia Caumette, Frédéric Garcia, Sylvain Poujol, Stéphane Culine, Frédéric Pinguet.   

Abstract

Perception of pain by the patient is frequently one of the early signs preceding a diagnosis of cancer and, later, a sinister sign of disease progression. Among opioid drugs, transdermal fentanyl has been evaluated in the treatment of moderate to severe cancer pain. The objective of this study was to investigate the intra- and interindividual variabilities in pharmacokinetics after fentanyl drug delivery by the transdermal fentanyl patch delivery system in patients with cancer pain. As a first step, a liquid chromatography-mass spectrometry method was developed for the determination of the analgesic fentanyl in human plasma. This method was validated over the concentration range 0.15-100 ng/mL. The study group consisted of 29 inpatients (18 men and 11 women; age range 29-80 years). The initial transdermal fentanyl delivery rate was chosen depending on the patient's analgesic requirements. For 20 patients, the initial TTS fentanyl delivery rate was 25 or 50 microg/h. For 6 patients, the initial delivery rate was 75-150 microg/h. Two patients received up to 300 microg/h fentanyl delivery rate, and 3 patients received up to 350 microg/h fentanyl delivery rate. Fifteen of the 29 patients received rescue doses of subcutaneous or oral morphine, and 26 patients received paracetamol with codeine (30 mg per os). Blood samples were collected at the following intervals: 2-5, 22-26, or 45-47 hours following fentanyl patch application. The severity of pain experienced by the patient was assessed thrice daily using a visual analogue scale. The study period was 46 days. Large patient-to-patient variations in pharmacokinetic parameters occurred, although intraindividual variability was limited. A mean bioavailability of 78% was estimated; the total clearance averaged 41 L/h. From 25 to 100 mug/h fentanyl delivery rate, the pharmacokinetics was linear. At the 2 highest doses, an increase of total clearance was observed (>60 L/h). For the whole group, transdermal fentanyl treatment provided good to excellent pain relief in the majority of patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16044107     DOI: 10.1097/01.ftd.0000160717.50704.42

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  13 in total

Review 1.  Clinical pharmacology of analgesic medicines in older people: impact of frailty and cognitive impairment.

Authors:  Andrew J McLachlan; Sally Bath; Vasi Naganathan; Sarah N Hilmer; David G Le Couteur; Stephen J Gibson; Fiona M Blyth
Journal:  Br J Clin Pharmacol       Date:  2011-03       Impact factor: 4.335

2.  Influence of hepatic impairment on the pharmacokinetics of the dopamine agonist rotigotine.

Authors:  Willi Cawello; Andreas Fichtner; Hilmar Boekens; Marina Braun
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-09-20       Impact factor: 2.441

Review 3.  Fentanyl Formulations in the Management of Pain: An Update.

Authors:  Stephan A Schug; Sonya Ting
Journal:  Drugs       Date:  2017-05       Impact factor: 9.546

4.  Effects of μ-opioid receptor modulation on the hippocampal network activity of sharp wave and ripples.

Authors:  Panagiotis Giannopoulos; Costas Papatheodoropoulos
Journal:  Br J Pharmacol       Date:  2013-03       Impact factor: 8.739

5.  Modified glasgow prognostic score predicting high conversion ratio in opioid switching from oral oxycodone to transdermal fentanyl in patients with cancer pain.

Authors:  Shu-Shan Jia; Li Shang; Ming-E Li; Dong-Mei Zhao; Wen-Hua Xu; Yao-Qi Wang
Journal:  Int J Clin Exp Med       Date:  2015-05-15

Review 6.  A review of factors explaining variability in fentanyl pharmacokinetics; focus on implications for cancer patients.

Authors:  Evelien J M Kuip; Maarten L Zandvliet; Stijn L W Koolen; Ron H J Mathijssen; Carin C D van der Rijt
Journal:  Br J Clin Pharmacol       Date:  2016-10-29       Impact factor: 4.335

Review 7.  Transdermal fentanyl: pharmacology and toxicology.

Authors:  Lewis Nelson; Robert Schwaner
Journal:  J Med Toxicol       Date:  2009-12

Review 8.  Pharmacokinetics of non-intravenous formulations of fentanyl.

Authors:  Jörn Lötsch; Carmen Walter; Michael J Parnham; Bruno G Oertel; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

9.  The efficacy of low-dose transdermal fentanyl in opioid-naïve cancer patients with moderate-to-severe pain.

Authors:  Jung Hun Kang; Sung Yong Oh; Seo-Young Song; Hui-Young Lee; Jung Han Kim; Kyoung Eun Lee; Hye Ran Lee; In Gyu Hwang; Se Hoon Park; Won Seok Kim; Young Suk Park; Keunchil Park
Journal:  Korean J Intern Med       Date:  2014-12-30       Impact factor: 2.884

10.  Beyond mean values: Quantifying intraindividual variability in pre-sleep arousal and sleep in younger and older community-dwelling adults.

Authors:  Kristy D Shoji; Caitlan A Tighe; Natalie D Dautovich; Christina S McCrae
Journal:  Sleep Sci       Date:  2015-03-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.